- Home
- ATNF vs ADTX Comparison
ATNF vs ADTX Comparison
Compare ATNF & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- ADTX
- Stock Information
- Founded
- ATNF 2016
- ADTX 2017
- Country
- ATNF United States
- ADTX United States
- Employees
- ATNF N/A
- ADTX N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- ADTX Health Care
- Exchange
- ATNF Nasdaq
- ADTX Nasdaq
- Market Cap
- ATNF 5.7M
- ADTX 5.3M
- IPO Year
- ATNF N/A
- ADTX 2020
- Fundamental
- Price
- ATNF $1.46
- ADTX $0.11
- Analyst Decision
- ATNF
- ADTX
- Analyst Count
- ATNF 0
- ADTX 0
- Target Price
- ATNF N/A
- ADTX N/A
- AVG Volume (30 Days)
- ATNF 1.1M
- ADTX 40.3M
- Earning Date
- ATNF 02-13-2025
- ADTX 11-18-2024
- Dividend Yield
- ATNF N/A
- ADTX N/A
- EPS Growth
- ATNF N/A
- ADTX N/A
- EPS
- ATNF N/A
- ADTX N/A
- Revenue
- ATNF N/A
- ADTX $212,107.00
- Revenue This Year
- ATNF N/A
- ADTX $95.61
- Revenue Next Year
- ATNF $54.15
- ADTX $1,584.79
- P/E Ratio
- ATNF N/A
- ADTX N/A
- Revenue Growth
- ATNF N/A
- ADTX N/A
- 52 Week Low
- ATNF $1.16
- ADTX $0.11
- 52 Week High
- ATNF $17.75
- ADTX $218.00
- Technical
- Relative Strength Index (RSI)
- ATNF 39.69
- ADTX 17.02
- Support Level
- ATNF $1.43
- ADTX $0.11
- Resistance Level
- ATNF $1.67
- ADTX $0.21
- Average True Range (ATR)
- ATNF 0.13
- ADTX 0.03
- MACD
- ATNF 0.00
- ADTX 0.02
- Stochastic Oscillator
- ATNF 21.82
- ADTX 2.35
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.